Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
recombinant interleukin-21 · 3 trials · 4 indications
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | - |
| B | EXPERIMENTAL | - |
| C | EXPERIMENTAL | - |
| D | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| recombinant interleukin-21 | DRUG | Administered i.v. in treatment cycles of 28 days. |
| caelyx (pegylated liposomal doxorubicin) | DRUG | Administered i.v. in treatment cycles of 28 days. |
| sunitinib | DRUG | Hard gelatine capsules, 12.5 mg |
Inclusion Criteria: * Advanced epithelial Ovarian Cancer (stage IIB-IV) * Persistent or progressive disease after or relapse within one year of completion of first line therapy * Measurable or assessable disease * Eastern Cooperative Oncology Group status less than or equal to 2 Exclusion Criteria...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
Recombinant interleukin-21 is an investigational cancer therapy being developed by Novo Nordisk A/S (NVO). It has been studied in Phase 2 clinical trials for malignant melanoma, ovarian cancer, and renal cell carcinoma. The drug is not approved and remains in clinical development.
Recombinant interleukin-21 is a form of the cytokine interleukin-21, which modulates immune responses. It is being studied for its potential to stimulate the immune system against cancer cells. The drug targets the interleukin-21 receptor pathway to enhance anti-tumor immunity.
Recombinant interleukin-21 is developed by Novo Nordisk A/S, a pharmaceutical company listed on the stock exchange under the ticker NVO. The company has sponsored Phase 2 clinical trials evaluating the drug in various cancer indications.
Recombinant interleukin-21 is in Phase 2 clinical development. It has completed three Phase 2 trials, with no active trials currently ongoing. The drug is investigational and has not received FDA approval.
Recombinant interleukin-21 has been studied in three completed Phase 2 trials: NCT00336986 for metastatic melanoma, NCT00523380 for ovarian cancer, and NCT00617253 for renal cell carcinoma in combination with sunitinib. These trials enrolled a total of 73 participants.
Recombinant interleukin-21 is also known as IL-21 or rIL-21. It is a recombinant form of the naturally occurring cytokine interleukin-21. The drug has been studied under these names in clinical trials for cancer.